Vaxin Inc., a clinical stage vaccine and immunotherapeutics company, has been granted Notices of Allowance from the USPTO for two new patents protecting elements of its hepatitis B and influenza vaccine candidates. The patents cover an aqueous formulation for Vaxin's HepTcell hepatitis B immunotherapy product and the intranasal administration of its NasoVax influenza vaccine to induce immune responses. With these additions, Vaxin now has 37 patents in 13 countries protecting its products. The company is on track to begin three phase 1 clinical trials within the next 9 months.

1. 1
VAXIN STRENGTHENS INTELLECTUAL PROPERTY PORTFOLIO
Gaithersburg, Maryland – July 21 2015- Vaxin Inc. today announced that it has added key patents to its
expanding Intellectual Property (IP) portfolio. The clinical stage vaccine and immunotherapeutics company
confirmed that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for two
patents that protect important elements of its Densigen platform technology for immunotherapeutic treatment
of Hepatitis B virus infection, and its RespirVec non-invasive adenoviral vector influenza vaccine. The patents
include U.S. Application Serial No. 13/977,265 (the ‘265 application) entitled “Fluorocarbon-Linked Peptide
Formulation”, and U.S. Application Serial No. 13/426,037 (the ‘037 application) entitled “Rapid and Prolonged
Immunologic-Therapeutic”.
A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an
application. Vaxin now has 37 patents protecting its products in 13 countries.
The ‘265 application is directed to a pharmaceutical formulation for Vaxin’s HepTcell Hepatitis B Immunotherapy
product candidate with claims to an aqueous acidic formulation for fluorocarbon-linked peptides. The issued
patent from this application is expected to expire in 2032.
The ‘037 application is directed to the use of Vaxin’s NasoVax influenza vaccine product candidate with claims
directed to inducing a protective immune response against the influenza virus following intranasal
administration. The issued patent from this application is expected to expire in 2032.
Scot Roberts, Vaxin’s CSO commented, ”Vaxin is a thriving company, set to begin phase 1 clinical studies in three
independent indications within the next 9 months, including a recently opened study with HepTcell in chronically
infected hepatitis B patients. These patent allowances demonstrate our continued commitment to innovation,
differentiation, and product promise.”
About Vaxin
Vaxin Inc. is a clinical stage biotechnology company developing next-generation vaccines and
immunotherapeutics to address significant public health and biodefense needs. By leveraging specific attributes
of its two independent and complementary platform technologies, Vaxin can rapidly design product candidates
against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. Our
Densigen™ T-cell platform technology is uniquely suited to direct the immune response against traditionally
difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system
against multiple target antigens instead of just one. Vaxin’s RespirVec™ platform utilizes convenient needle-free
intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional
vaccines. Vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective
alternative to current products. www.vaxin.com.
Vaxin Contact: Bill Enright, President & CEO, Phone: 240-654-1450, Email: enright@vaxin.com